Welcome to our dedicated page for Alvotech SEC filings (Ticker: ALVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alvotech filings document a foreign private issuer focused on biosimilar medicine development and manufacturing. Its Form 6-K reports furnish press releases, earnings materials, business updates and exhibits that are incorporated by reference into registration statements on Forms F-3, F-3ASR and S-8 where applicable.
The disclosure record covers financial results, the Form 20-F annual reporting framework, FDA and cGMP matters involving the Reykjavik manufacturing facility, biosimilar clinical and pharmacokinetic updates, supply and commercialization agreements, patent-settlement disclosures, executive-team changes and notifications of manager-related share transactions reported through Luxembourg CSSF forms. These filings also document governance, capital-market registrations and recurring regulatory topics for Alvotech’s biosimilar portfolio.
Alvotech has reached a global licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide for its aflibercept biosimilar to Eylea® 2mg, already approved in the EEA, United Kingdom and Japan.
The deal grants Alvotech worldwide rights to manufacture and supply its commercial partners and sets staged launch dates: marketing and sales from January 1, 2026 in the United Kingdom and Canada, from May 1, 2026 in the European Economic Area and other non‑U.S. countries, and from November 1, 2026 in Japan for all approved indications, alongside a previously announced Q4 2026 license entry date for the U.S., pending regulatory approval.
Alvotech furnished a Form 6-K describing recent share transactions by a person closely associated with its CEO and chairman, Róbert Wessman, and how these were reported to the Luxembourg regulator. The company notes that this report, excluding Exhibits 99.1 and 99.2, is incorporated by reference into several existing shelf and employee share plan registration statements.
Alvotech states that ATP Holdings ehf. reported acquiring 4,812,257 Alvotech shares on December 17, 2025 at SEK 44.06 per share and selling 2,110,640 shares on December 19, 2025 at the same price, based on forms filed with the Luxembourg CSSF. The company explains that this corrects an earlier announcement that had mistakenly described the December 19, 2025 transaction as an acquisition. The detailed regulatory notifications are furnished as Exhibits 99.1 and 99.2, which are not deemed filed for liability purposes.
Alvotech reported share purchases in the company by entities closely associated with its leadership. On January 6, 2026, it announced that Alvogen Lux Holdings S.a. r.l., a person closely associated with senior management and board members, acquired 7,007,321 Alvotech shares on December 17, 2025 at SEK 44.06 per share. The company also announced that ATP Holdings ehf. acquired 4,812,257 Alvotech shares on December 17, 2025 at SEK 44.06 per share and a further 2,110,640 shares on December 19, 2025 at the same price. These transactions were notified to the Luxembourg financial regulator using HOS-2 forms, which are furnished as exhibits to this report.
Alvotech is implementing a planned CEO succession in which founder Róbert Wessman will leave the Chief Executive Officer role at the end of the first quarter of 2026 and continue as full-time Executive Chairman. Lisa Graver, currently a board member and long-time colleague of Wessman, has been appointed to succeed him as CEO, with a transition process beginning immediately and her stepping down from the board once she assumes the role. The company highlights that its biosimilar platform now includes a pipeline of 30 products in development and five biosimilars already approved and marketed globally, underscoring the leadership change as part of the next phase of its growth.
Alvotech is implementing a planned CEO succession in which founder Róbert Wessman will leave the Chief Executive Officer role at the end of the first quarter of 2026 and continue as full-time Executive Chairman. Lisa Graver, currently a board member and long-time colleague of Wessman, has been appointed to succeed him as CEO, with a transition process beginning immediately and her stepping down from the board once she assumes the role. The company highlights that its biosimilar platform now includes a pipeline of 30 products in development and five biosimilars already approved and marketed globally, underscoring the leadership change as part of the next phase of its growth.
Alvotech provided a business update and detailed new financing. The company reaffirmed its updated 2025 outlook, expecting total revenue between $570 and $600 million and adjusted EBITDA of $130 to $150 million. For 2026, it targets total revenue of $650 to $700 million and adjusted EBITDA of $180 to $220 million. This guidance factors in potential delays and Complete Response Letters from the U.S. FDA for several biosimilar candidates, assumes possible receipt of a CRL for AVT03, and is based on an assumption that U.S. marketing approvals for pending applications are received by late 2026.
The company also noted a settlement and license agreement with Regeneron Pharmaceuticals that grants AVT06, its proposed Eylea biosimilar, a U.S. license entry date in the fourth quarter of 2026, or earlier if certain conditions are met. Separately, Alvotech completed an offshore offering of $108 million senior unsecured convertible bonds due 2030, carrying a 6.875% coupon and initially convertible into Swedish Depositary Receipts at $5.9224 per SDR, a 25% premium to a $4.7379 reference price. Net proceeds are intended to be used to invest in the R&D pipeline, scale and product launches.
Alvotech reported that its product AVT03, a biosimilar to Prolia and Xgeva (both denosumab), has been approved for marketing in the European Economic Area.
This approval means Alvotech can market AVT03 across the EEA, potentially opening a new revenue stream in the osteoporosis and oncology-related bone disease markets targeted by the reference medicines. The news was communicated through a press release dated November 24, 2025, which is furnished as an exhibit to this report.
Alvotech filed a Form 6-K to share regulatory news about one of its biosimilar products. The company announced that AVT05, a biosimilar to Simponi (golimumab), has been approved for marketing in the European Economic Area. This approval means Alvotech can commercialize AVT05 in European markets covered by the EEA, potentially expanding its biosimilar portfolio reach. The filing also notes that the accompanying press release is furnished as an exhibit but is not incorporated by reference into the company’s securities registration statements.
Alvotech submitted a Form 6-K as a foreign private issuer to furnish a recent press release to investors. The filing states that, on November 12, 2025, the company issued a press release announcing its earnings for the first nine months of 2025 and providing a business update. The Form 6-K also clarifies that, except for the attached press release, the report is incorporated by reference into several existing Alvotech shelf and employee share plan registration statements, which means those registrations now formally include this new information.
Alvotech furnished a Form 6-K noting that a justice of the UK High Court rejected an injunction request from Regeneron Pharmaceuticals, joined by Bayer, relating to manufacturing activities at Alvotech’s UK contract manufacturing organization for its Eylea biosimilar candidate, AVT06. The company attached a press release as Exhibit 99.1.
The Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed.
Alvotech filed a Form 6-K reporting that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its biosimilar to Simponi (golimumab), marketed as Gobivaz. The company furnished a press release announcing the approval as Exhibit 99.1.
The report states that this Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed, under the Exchange Act.